Gene editing of deep intronic mutations
AssigneeGenzyme Corporation
InventorsGuoxiang RUAN, Abraham SCARIA
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)—CRISPR associated (Cas) (CRISPR-Cas) system. In some aspects, provided herein is a self-limiting CRISPER-Cas system.
Claims20
1-458. (canceled)
A composition for limiting expression of Cas9 protein in a cell comprising:
- a) a nucleic acid encoding at least one guide RNA comprising a first guide RNA that hybridizes to a first target site, wherein the first target site is located in the cell's genome,
- b) a Cas expression cassette, wherein the Cas expression cassette comprises:
- i) a nucleotide sequence encoding a Cas9 protein, and
- ii) a cleavage site that is a nucleotide sequence comprising the first target site,
- wherein the cleavage site is capable of being cleaved by the Cas9 protein to thereby reduce expression of the Cas9 protein, as compared to expression of the Cas9 protein prior to cleavage of the Cas expression cassette.
A composition for limiting expression of Cas9 protein in a cell comprising:
- a) a nucleic acid encoding at least one guide RNA comprising a first guide RNA that hybridizes to a first target site and a second guide RNA that hybridizes to a second target site,
- wherein the first and second target sites are located in the cell's genome,
- b) a Cas expression cassette, wherein the Cas expression cassette comprises:
- i) a nucleotide sequence encoding a Cas9 protein, and
- ii) a first cleavage site that is a nucleotide sequence comprising the first or second target site,
- wherein the first cleavage site is capable of being cleaved by the Cas9 protein to thereby reduce expression of the Cas9 protein, as compared to expression of the Cas9 protein prior to cleavage of the Cas expression cassette.
A composition for limiting expression of Cas9 protein in a cell comprising:
- a) a nucleic acid encoding at least one guide RNA comprising a first guide RNA that hybridizes to a first target site and a second guide RNA that hybridizes to a second target site,
- wherein the first and second target sites are located in the cell's genome and located on opposite strands of a target gene,
- wherein the target gene comprises a gene comprising a deep intronic mutation;
- and
- b) a Cas expression cassette, wherein the Cas expression cassette comprises:
- i) a nucleotide sequence encoding a Cas9 protein, and
- ii) a first cleavage site that is a nucleotide sequence comprising the first or second target site,
- wherein the first cleavage site is capable of being cleaved by the Cas9 protein to thereby reduce expression of the Cas9 protein, as compared to expression of the Cas9 protein prior to cleavage of the Cas expression cassette.
Dependencies are inferred from the claim text.